Zobrazeno 1 - 10
of 605
pro vyhledávání: '"Aman U Buzdar"'
Autor:
Aman U. Buzdar
Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of e
Autor:
Junmei Cairns, James N. Ingle, Tanda M. Dudenkov, Krishna R. Kalari, Erin E. Carlson, Jie Na, Aman U. Buzdar, Mark E. Robson, Matthew J. Ellis, Paul E. Goss, Lois E. Shepherd, Barbara Goodnature, Matthew P. Goetz, Richard M. Weinshilboum, Hu Li, Mehrab Ghanat Bari, Liewei Wang
Publikováno v:
JCI Insight, Vol 5, Iss 16 (2020)
Aromatase inhibitors (AIs) reduce breast cancer recurrence and prolong survival, but up to 30% of patients exhibit recurrence. Using a genome-wide association study of patients entered on MA.27, a phase III randomized trial of anastrozole versus exem
Externí odkaz:
https://doaj.org/article/d318692f04d14855bf3070f9a33fe2ab
Autor:
David S. Hong, Funda Meric-Bernstam, J. Jack Lee, Razelle Kurzrock, Aman U. Buzdar, Suzanne E. Davis, Dwana Sanders, Kenneth R. Hess, Chad Tang
Number of submitted ICT department trials as a function of time.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cfaa1d59c72a772e1977ddf20438505
https://doi.org/10.1158/1078-0432.22464809
https://doi.org/10.1158/1078-0432.22464809
Autor:
Jeffrey T. Chang, Stacy L. Moulder, Lei Huo, Rosalind P. Candelaria, Gaiane M. Rauch, Elizabeth A. Mittendorf, Alistair M. Thompson, Gabriel N. Hortobagyi, Aman U. Buzdar, Xiaoxian Li, Luis Baez, Bora Lim, Rashmi K. Murthy, Naoto T. Ueno, Jennifer K. Litton, Banu K. Arun, Senthilkumar Damodaran, Debu Tripathy, Vicente Valero, Alyson R. Clayborn, Elizabeth E. Ravenberg, Jason B. White, Qing-Qing Ding, Beatriz E. Adrada, Ryan Sun, Nour Abuhadra, Clinton Yam
Supplementary Figure from Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::031d63d3a2dd436e50408dd615422603
https://doi.org/10.1158/1078-0432.22487816.v1
https://doi.org/10.1158/1078-0432.22487816.v1
Autor:
Jeffrey T. Chang, Stacy L. Moulder, Lei Huo, Rosalind P. Candelaria, Gaiane M. Rauch, Elizabeth A. Mittendorf, Alistair M. Thompson, Gabriel N. Hortobagyi, Aman U. Buzdar, Xiaoxian Li, Luis Baez, Bora Lim, Rashmi K. Murthy, Naoto T. Ueno, Jennifer K. Litton, Banu K. Arun, Senthilkumar Damodaran, Debu Tripathy, Vicente Valero, Alyson R. Clayborn, Elizabeth E. Ravenberg, Jason B. White, Qing-Qing Ding, Beatriz E. Adrada, Ryan Sun, Nour Abuhadra, Clinton Yam
Purpose:Metaplastic breast cancer (MpBC) is a rare subtype of breast cancer that is commonly triple-negative and poorly responsive to neoadjuvant therapy in retrospective studies.Experimental Design:To better define clinical outcomes and correlates o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e5a5c1b653f1a2a1baf688e0d7014e2
https://doi.org/10.1158/1078-0432.c.6532592.v1
https://doi.org/10.1158/1078-0432.c.6532592.v1
Autor:
David S. Hong, Funda Meric-Bernstam, J. Jack Lee, Razelle Kurzrock, Aman U. Buzdar, Suzanne E. Davis, Dwana Sanders, Kenneth R. Hess, Chad Tang
Purpose: Information on processes for trials assessing investigational therapeutics is sparse. We assessed the trial development processes within the Department of Investigational Cancer Therapeutics (ICT) at MD Anderson Cancer Center (Houston, TX) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::606cd7308bdac2a4a2d6f8109878e8dc
https://doi.org/10.1158/1078-0432.c.6525809.v1
https://doi.org/10.1158/1078-0432.c.6525809.v1
Autor:
Jeffrey T. Chang, Stacy L. Moulder, Lei Huo, Rosalind P. Candelaria, Gaiane M. Rauch, Elizabeth A. Mittendorf, Alistair M. Thompson, Gabriel N. Hortobagyi, Aman U. Buzdar, Xiaoxian Li, Luis Baez, Bora Lim, Rashmi K. Murthy, Naoto T. Ueno, Jennifer K. Litton, Banu K. Arun, Senthilkumar Damodaran, Debu Tripathy, Vicente Valero, Alyson R. Clayborn, Elizabeth E. Ravenberg, Jason B. White, Qing-Qing Ding, Beatriz E. Adrada, Ryan Sun, Nour Abuhadra, Clinton Yam
Supplementary Table from Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61d6ca34b97960334d9c1729a48f9a86
https://doi.org/10.1158/1078-0432.22487813.v1
https://doi.org/10.1158/1078-0432.22487813.v1
Autor:
Clinton Yam, Nour Abuhadra, Ryan Sun, Beatriz E. Adrada, Qing-Qing Ding, Jason B. White, Elizabeth E. Ravenberg, Alyson R. Clayborn, Vicente Valero, Debu Tripathy, Senthilkumar Damodaran, Banu K. Arun, Jennifer K. Litton, Naoto T. Ueno, Rashmi K. Murthy, Bora Lim, Luis Baez, Xiaoxian Li, Aman U. Buzdar, Gabriel N. Hortobagyi, Alistair M. Thompson, Elizabeth A. Mittendorf, Gaiane M. Rauch, Rosalind P. Candelaria, Lei Huo, Stacy L. Moulder, Jeffrey T. Chang
Publikováno v:
Clin Cancer Res
Purpose:Metaplastic breast cancer (MpBC) is a rare subtype of breast cancer that is commonly triple-negative and poorly responsive to neoadjuvant therapy in retrospective studies.Experimental Design:To better define clinical outcomes and correlates o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::338df94510fedde500728928d4f7d9fc
https://europepmc.org/articles/PMC9250637/
https://europepmc.org/articles/PMC9250637/
Autor:
Barbara Goodnature, Junmei Cairns, Richard M. Weinshilboum, Erin E. Carlson, Matthew J. Ellis, Liewei Wang, Krishna R. Kalari, Abraham Eyman Casey, Poulami Barman, Tufia C. Haddad, Lois E. Shepherd, Mark E. Robson, Aman U. Buzdar, Tanya L. Hoskin, James N. Ingle, Matthew P. Goetz, Paul E. Goss
Publikováno v:
Pharmacogenetics and Genomics. 31:1-9
Objectives Based on our previous findings that postmenopausal women with estrone (E1) and estradiol (E2) concentrations at or above 1.3 pg/ml and 0.5 pg/ml, respectively, after 6 months of adjuvant anastrozole therapy had a three-fold risk of recurre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2662ea52f225c20934e99c34df5aa0e
https://doi.org/10.1097/fpc.0000000000000415
https://doi.org/10.1097/fpc.0000000000000415
Publikováno v:
Holland-Frei Cancer Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38a78eaa3fd10d3bd3e5f1af8d892802
https://doi.org/10.1002/9781119000822.hfcm062.pub2
https://doi.org/10.1002/9781119000822.hfcm062.pub2